Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic
  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024

PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond Vennare, Chief Executive Officer, is scheduled to deliver a company overview presentation at the BIO International Convention 2024, which is being held June 3-6 in San Diego.

“We are very pleased to participate in this year’s Bio International Convention, which is the premier gathering of biopharmaceutical stakeholders from around the world,” stated Raymond Vennare, Chief Executive Officer of Predictive Oncology. “With our unique portfolio of assets, which includes advanced AI and active machine learning capabilities, a CLIA-certified wet lab, and a vast biobank of hundreds of thousands of tumor samples and pathology slides, we are able to confidently support our predictions through real-world experimentation by introducing tumor heterogeneity into the earliest phases of drug discovery. I look forward to highlighting these capabilities, which I believe set us apart from our peers and will allow us to be a leader in this rapidly growing field of AI-driven drug discovery.”

Presentation details:

Title:Novel AI Driven Insights to Guide Early Drug Discovery
Date/time:Monday, June 3rd, 3:45pm PDT (6:45pm EDT)
For more information: https://convention.bio.org/about-bio
  

About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA. 

Investor Relations Contact
Tim McCarthy
LifeSci Advisors, LLC
tim@lifesciadvisors.com

Forward-Looking Statements: 
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.